Intacoxia 120 Tablet contains Etoricoxib 120 mg, a selective cyclooxygenase-2 (COX-2) inhibitor used primarily for the management of pain and inflammation associated with osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute gouty arthritis. By selectively inhibiting the COX-2 enzyme, Etoricoxib reduces the synthesis of prostaglandins responsible for inflammation and pain, while sparing COX-1, thereby minimizing gastrointestinal adverse effects commonly seen with non-selective NSAIDs. Intacoxia 120 is indicated for short-term and long-term treatment of musculoskeletal disorders where inflammation and pain are predominant symptoms. It is also effective in managing acute pain following dental surgery and other minor surgical procedures. The recommended dose should be individualized based on the severity of symptoms and patient response, with caution advised in patients with cardiovascular risk factors, renal impairment, or hepatic dysfunction. Contraindications include hypersensitivity to Etoricoxib or other NSAIDs, active peptic ulceration, and severe heart failure. Common adverse effects may include headache, dizziness, hypertension, and gastrointestinal discomfort. Patients should be monitored regularly for blood pressure, renal function, and signs of gastrointestinal bleeding during therapy. Intacoxia 120 Tablet should be used under medical supervision to ensure optimal therapeutic outcomes and safety.